
REPUBLIC OF LEBANON MINISTRY OF PUBLIC HEALTH Lebanon Clinical Trials Registry

A Phase 2a study to assess efficacy and safety of VIT-2763 in subjects with sickle cell disease

23/08/2025 04:45:25

Primary registry identifying number	Protocol number		
_BCTR2021064783	VIT-2763-SCD-202		
MOH registration number			
Study registered at the country of origin	Study registered at the country of origin: Specify		
No	No. Prevalence of the disease is low in the country of origin Switzerland		
Type of registration	Type of registration: Justify		
Prospective	N/A		
Date of registration in national regulatory agency			
Primary sponsor	Primary sponsor: Country of origin		
Vifor (International) Inc.	Switzerland		
Date of registration in primary registry Date of registration in national regulatory agency			
15/07/2021			
Public title	Acronym		
A Phase 2a study to assess efficacy and safety of VIT-2763 in subjects with sickle cell disease			
Scientific title	Acronym		
A Phase 2a, double-blind, randomised, placebo-controlled, ascending dose and maintenance dose, efficacy, and safety study of multiple doses of VIT-2763 in subjects with sickle cell disease			
Brief summary of the study: English			
This study is is a Phase 2a, double-blind, randomised, placebo- controlled, ascending dose and maintenance dose, efficacy, and safety study of multiple doses of VIT-2763 in subjects with sickle cell disease. The primary objective of this study is to explore the effect of VIT-2763 on markers of haemolysis.			
Brief summary of the study: Arabic			
ة للتحكم الوهمي ، جرعة تصاعدية وجرعة صيانة وفعالية ودراسة2هذه الدراسة عبارة عن مرحلة جلية. الهدف الأساسي من هذه الدراسة هو استكثىاف تأثير VIT-2763 سلامة لجرعات متعددة من على علامات انحلال الدم VIT-2763	اً ، مزدوجة التعمية ، عشوائية ، خاضعا في الأشخاص المصابين بمرض الخلايا المد		
Health conditions/problem studied: Specify			
sickle cell disease (SCD) (sickle haemoglobin (HbS)/S or HbS/ β T0gen	otype)		
Interventions: Specify			
30 mg (Cohorts 1a and 1b) or 60 mg VIT-2763 (Cohorts 2a and 2b) an	omised in a 1:1:1:1:1 ratio into 4 VIT-2763 dose groups to receive either		

During Part B, subjects in Cohort 1a (VIT-2763 30 mg) and Cohort 2a (VIT-2763 60 mg) will remain on the same VIT-2763 dose as in Part A; whereas, subjects in Cohort 1b and Cohort 2b will continue with an increased dose of VIT-2763, 60 mg and 120 mg, respectively. Subjects randomised to placebo during Part A (Cohort 3) will continue unchanged during Part B.



MINISTRY OF PUBLIC HEALTH

REPUBLIC OF LEBANON Lebanon Clinical Trials Registry

Key inclusion and exclusion criteria: Inclusion criteria

Inclusion Criteria:

1. Subject has provided the appropriate written informed consent before any study-specific procedures are performed including screening procedures.

2. Ability to understand the requirements of the study and abide by the study restrictions, and agreement to return for the required assessments.

3. Male or female subjects with confirmed diagnosis of SCD, including HbS/S or HbS/ β T0 genotype.

4. Subjects who had at least 1 and no more than 6 VOC episodes reported within 12 months prior to screening. Note: A VOC episode is defined as a

documented episode of acute chest syndrome or acute painful crisis for the main indication of SCD, which led to health-professional instructed prescription or use of analgesics for moderate to severe pain.

5. 18 to 50 years of age inclusive at the time of screening.

6. Body weight ≥50 kg and ≤100 kg at screening and baseline.

7. Absolute reticulocyte count and percentage reticulocyte count >1.5 × upper limit of normal (ULN) during screening.

8. Subjects on concomitant hydroxyurea must be on a stable dose (mg/kg) for ≥3 months prior to screening Visit V1. There should be no planned dose adjustments during the course of the study in the opinion of the Investigator.

9. Female subjects of childbearing potential, must have negative pregnancy tests at screening and before randomisation, must have stopped breastfeeding as of first dose, and must either commit to true abstinence from heterosexual contact (which must be reviewed on a monthly basis and source documented) or must be willing to use adequate contraceptive precautions, i.e., highly effective method of birth control. Abstinence should only be used as a contraceptive method if it is in line with the subjects' usual and preferred lifestyle, and periodic abstinence (calendar, symptothermal, postovulation methods) is not an acceptable method of contraception. Female subjects must agree to use adequate contraception during the study and for 1 month after the last dose of investigational medicinal product (IMP) or according to local requirements, whichever is longer. Effective contraception (highly effective method of birth control, i.e., with a failure rate of <1% per year, when used consistently and correctly) such as implants, injectables, combined oral contraceptives (see below), intrauterine devices, sexual abstinence, or vasectomised partner must be used. Non-childbearing potential includes being surgically sterilised at least 6 months prior to the study.

Note: For female subjects participating in this study, continuous use of hormonal contraception alone is not sufficient, because potential interactions

via cytochrome P450 (CYP) enzymes may alter the efficacy of hormonal contraception. The continuous use of hormonal contraception by a female

subject should be combined with the use of a condom by the male partner; the condom should then be used together with a spermicide or adequate and approved alternatives.

10. Male subjects must practice true abstinence (abstinence should only be used as a contraceptive method if it is in line with the subjects' usual and preferred lifestyle, and it is continuous throughout the study) or agree to use a condom during sexual contact with a pregnant female or a female of childbearing potential while participating in the study, and for at least 1 month-sufficiently exceeding 5 times the mean t1/2 of VIT -2763 based on multiple dose human PK data following IMP discontinuation, even if he has undergone a successful vasectomy.

Key inclusion and exclusion criteria: Gender Key inclusion and exclusion criteria: Specify gender Both Key inclusion and exclusion criteria: Age minimum Key inclusion and exclusion criteria: Age maximum 18 50 Key inclusion and exclusion criteria: Exclusion criteria Exclusion Criteria Subjects with confirmed diagnosis of HbS/βT+ genotype or HbSC disease. 2. Hb level <6.0 g/dl or >10.4 g/dl at screening Visit V1 (based on local laboratory value). Note: The Hb value at screening Visit V1 will be used for eligibility determination. However, the baseline Hb value determined at Visit V2 (Day 1

pre-dose) also needs to be within the above specified range.

3. Having received RBC transfusion therapy within 4 weeks prior to screening, or ongoing or planned RBC transfusion therapy during the course of the study (including chronic, prophylactic, or preventive transfusion to treat SCD).

4. Ferritin level <30 µg/l or calculated transferrin saturation (TSAT) level <25% or total iron-binding capacity (TIBC) level <250 µg/dl at screening.

5. Subjects being hospitalised for SCD-related events (including pain crisis and VOC) within 30 days before the screening visit. Note: SCD must have been the main cause for the hospitalisation to fulfil this criterion.

6. Chronic liver disease or history of liver cirrhosis, and/or alanine aminotransferase or aspartate aminotransferase, above 3-fold the ULN range at

baseline.

7. Estimated glomerular filtration rate (eGFR) <45 ml/min/1.73 m2, and/or significant urinary albumin/creatinine ratio >30 mg/g (>3.39 mg/mmol) at


screening or on chronic dialysis. Note: eGFR should be estimated according to Chronic Kidney Disease Epidemiology Collaboration formula (CKD-EPI).

8. Newly diagnosed folate deficiency anaemia (i.e., folic acid <2 ng/ml), which is considered clinically relevant by the Investigator at screening. Subjects with known folate deficiency anaemia who are on ≥12 weeks stable replacement therapy at screening are eligible. Note: A subject fulfilling this criterion will be excluded but can be re-screened at a later time point.

9. Subjects with history of partial or total splenectomy within 6 months prior tothe screening visit.

10. Any history or clinically important finding of cardiac or pulmonary disorders, including (but not limited to) clinically relevant or uncontrolled cardiac

arrhythmia, cardiomyopathy, coronary disease (unstable angina pectoris or myocardial infarction or elective coronary intervention), valve disorder. or



REPUBLIC OF LEBANON MINISTRY OF PUBLIC HEALTH Lebanon Clinical Trials Registry

heart failure according to New York Heart Association classification 3-4.

11. Known pulmonary hypertension, defined as a tricuspid regurgitant velocity (TRV) ≥2.5 m/s, NT-proBNP ≥160 pg/ml or confirmed by right heart

catheterisation.

12. Any clinically relevant abnormal 12-lead electrocardiogram (ECG) finding during screening or prior to randomisation (as deemed by the Investigator)including (but not limited to) any of the following:

PR interval >0.21 seconds

• Evidence or history of second- or third-degree atrioventricular block

• QRS interval >0.12 seconds

Family history of long-QT syndrome or sudden death without a preceding diagnosis of a condition that could be causative of sudden death (such as known coronary artery disease, congestive heart failure, or terminal cancer), or subjects with QT interval corrected (QTcF) >450 msec.
 Clinically significant bacterial, fungal, parasitic, or viral infection which requires therapy. Note: A subject meeting this criterion should delay screening and/or enrolment for a minimum of 2 weeks, or if excluded can be re-screened at maximum 2 times at a later time point.
 Known history, and/or positive result on screening for hepatitis B surface antigen, hepatitis B virus, hepatitis C virus, or HIV infection. Note: Subjects with known hepatitis B surface antigen positivity and/or hepatitis C virus antibody positivity will be allowed to participate only if the disease has been treated efficiently/is not active.

• Known active COVID-19 infection (positive result of a SARS-Cov-2 virus test (nucleic acid or antigen detection) within 2 weeks preceding screening), or any other active infection. Note: A subject who tested positive within 2 weeks preceding screening or during screening will be excluded but can be re-screened at a later time point as per Investigator's judgement and if confirmation of a negative SARS-CoV-2 test is available based on standard of care.

15. Use of any prohibited medication(s), including (but not limited to):

• Prior or concomitant use of any medication that is known to prolong the QT/QTc interval or the PR/QRS interval, within 3 weeks prior to screening and until end of study (EoS).

• Previous oral or intravenous iron therapy ≤4 weeks prior to screening and until EoS.

• Any drug that is metabolised mainly via CYP 3A4 and/or CYP 2D6 (except hormonal contraceptives that have been used by females at constant doses at minimum for 4 weeks prior to screening), or any known strong CYP 3A4 or CYP 2D6 inhibitor or inducer, or known P-glycoprotein (P-gp) inhibitors as of 4 weeks prior to screening and until EoS.

• Receipt of HbS polymerisation inhibitors (e.g., voxelotor), I-glutamine, erythropoietin stimulating/maturation agent treatment, crizanlizumab or any other haematopoietic growth factor treatment within 8 weeks prior to screening Visit V1 and until EoS, or anticipated need for such agents during the study.

• Any prior gene therapy.

• Use of chronic anticoagulant therapy unless treatment stopped at least 28 days prior to randomisation. Anticoagulant therapies used for prophylaxis for surgery or high-risk procedures as well as low molecular weight heparin for superficial venous thrombosis and chronic aspirin are allowed.

• Participation in any other clinical study with an investigational product <30 days prior to screening Visit V1 and until EoS.

16. Known sensitivity to any components of the study products to be administered.

17. Previous participation to this study with at least one administration of the IMP.

18. History of drug or alcohol abuse within 2 years prior to screening.

19. Pregnant (e.g., positive pregnancy test) or females currently breastfeeding.

20. History or known concomitant solid tumours and/or haematological malignancies unless resolved in the ≥5 past years, except for basal or squamous cell carcinoma of the skin, carcinoma in situ of the cervix or breast, incidental histologic finding of prostate cancer (T1a or T1b according to the Classification of Malignant Tumours clinical staging system).

21. Vulnerable subjects (e.g., subjects kept in detention, protected adults under guardianship, trusteeship, and soldiers) or subjects committed to an institution by governmental or juridical order, and any other vulnerable subjects.

22. Unable to take and absorb oral medications, unable to swallow Size 0 capsules.

23. Known significant medical condition(s), anticipated need for major surgery during the study, or any other kind of disorder that may be associated with increased risk to the subject, or may interfere with study assessments, outcomes, or the ability to provide written informed consent or comply with study procedures, in the Investigator's opinion.

24. Acute peptic stomach or duodenal ulcer in the previous 6 months before screening.

25. Any employee or their close relatives of the Sponsor, or of a Contract Research Organisation (CRO), or a study site involved in the trial.

Type of study

Interventional

Type of intervention Pharmaceutical	Type of intervention: Specify type N/A
Trial scope Other	Trial scope: Specify scope
Study design: Allocation	Study design: Masking
Randomized controlled trial	Blinded (masking used)
Study design: Control	Study phase
Placebo	2
Study design: Purpose	Study design: Specify purpose
Treatment	N/A

REPUBLIC OF LEBANON MINISTRY OF PUBLIC HEALTH	ebanon Clinical Trials Registry
Study design: Assignment Parallel	Study design: Specify assignment N/A
IMP has market authorization	IMP has market authorization: Specify
Νο	
Name of IMP	Year of authorization Month of authorization
VIT-2763	
Type of IMP	
Cell therapy	
Pharmaceutical class	
VIT-2763 is a Ferroportin (FPN) inhibitor and hepcidin-mimetic.	
Therapeutic indication	
Sickle cell disease.	
Therapeutic benefit	
VIT-2763 is developed as a novel oral drug targeting FPN, and iron overload and conditions in which iron metabolism is involve erythropoiesis, including (but not limited to) hereditary haemoch thalassaemia and SCD), or myeloproliferative/dysplastic disord myelodysplastic syndrome, respectively). Furthermore, the oral FPN inhibitor VI haemolysis, haemodynamics, and prevention of vaso-occlusior	ed: ineffective or otherwise disturbed nromatosis, haemoglobinopathies (e.g., ers (e.g., polycythaemia vera and T-2763 has shown positive results on
Study model	Study model: Explain model
N/A	N/A
Study model: Specify model N/A	
Time perspective	Time perspective: Explain time perspective
N/A	N/A
Time perspective: Specify perspective	
N/A	
Target follow-up duration	Target follow-up duration: Unit
Number of groups/cohorts	
Biospecimen retention	Biospecimen description
Samples without DNA	Blood and urine samples will be collected for routine clinical safety laboratory assessments according to the schedule of assessments
Target sample size	Actual enrollment target size



20	
Date of first enrollment: Type Anticipated	Date of first enrollment: Date 30/09/2021
Date of study closure: Type Anticipated	Date of study closure: Date 30/09/2022
Recruitment status Pending	Recruitment status: Specify
Date of completion	
IPD sharing statement plan No	IPD sharing statement description NA
Additional data URL	
Admin comments	
Trial status Approved	

Secondary Identifying Numbers		
Full name of issuing authority Secondary identifying number		
ЕМА	2020-005072-34	
FDA US IND	147878	

Sources of Monetary or Material Support

Name

25

Vifor (International) Inc.

Secondary Sponsors

Name

Not Applicable





Contact for Public/Scientific Queries						
Contact type	Contact full name	Address	Country	Telephone	Email	Affiliation
Public	Aziz Zoghbi	MCT-CRO, Berytech Technology and Health, 5th Floor Damascus Road, Beirut, Lebanon	Lebanon	009611612 500	aziz.zoghbi@mct -cro.com	Regional Manager
Scientific	Ali Taher	American university of Beirut Medical Center, Beirut	Lebanon	009613755 669	ataher@aub.edu. lb	PI
Scientific	Adlette Inati	Nini Hopsital, Tripoli	Lebanon	009613228 033	adlette.inati@lau. edu.lb	PI
Scientific	Suzanne Koussa	Chronic Care Center, Hazmieh, Lebanon	Lebanon	009613899 511	suzkocha@hotm ail.com	PI

Centers/Hospitals Involved in the Study				
Center/Hospital name	ter/Hospital name Name of principles investigator Principles investigator Speciality Ethical appr		Ethical approval	
Chronic Care Center	Dr. Suzanne Koussa	Hematology and Oncology	Pending	
American University of Beirut Medical Center	Dr. Ali Taher	Hematology and Oncology	Pending	
Nini Hospital	Dr. Adlette Inati	Hematology and Oncology	Approved	

Ethics Review				
Ethics approval obtained	Approval date	Contact name	Contact email	Contact phone
Nini Hospital	20/04/2021	Kamleh Ibrahim	kamleh.ibrahim@hopitalnini.com	00961 6 431400 ext 1062

Countries of Recruitment
Name
Lebanon
United States of America
United Kingdom
Greece



REPUBLIC OF LEBANON MINISTRY OF PUBLIC HEALTH Lebanon Clinical Trials Registry

Health Conditions or Problems Studied			
Condition Code Keyword			
sickle cell disease	Sickle-cell disorders (D57)	sickle cell disease	

Interventions			
Intervention	Description	Keyword	
VIT-2763 oral capsules of 2 dosage strengths (30 mg and 60 mg)	□ Treatment Group 1a: 1 capsule of 30 mg VIT- 2763 in the morning and 1 capsule of placebo in the evening for 8 weeks □ Treatment Group 1b: 1 capsule of 30 mg VIT-2763 in the morning and 1 capsule of placebo in the evening for 4 weeks followed by 1 capsule of 30 mg VIT-2763 in the morning and 1 capsule of 30 mg VIT-2763 in the evening for 4 weeks □ Treatment Group 2a: 1 capsule of 30 mg VIT-2763 in the evening and 1 capsule of 30 mg VIT-2763 in the evening for 8 weeks □ Treatment Group 2b: 1 capsule of 30 mg VIT-2763 in the morning and 1 capsule of 30 mg VIT-2763 in the evening for 4 weeks followed by 1 capsule of 60 mg VIT-2763 in the morning and 1 capsule of 60 mg VIT-2763 in the evening for 4 weeks □ Treatment Group 3: 1 capsule of placebo in the morning and 1 capsule of placebo in the evening for 8 weeks.	VIT-2763	

Primary Outcomes			
Name	Time Points	Measure	
Mean change in heamolysis marker	from baseline to after 8 weeks treatment	reduction of indirect bilirubin	



Key Secondary Outcomes		
Name	Time Points	Measure
Frequency and severity of reported or observed AEs by SOC and PTs	up to 4 weeks after EoT	All AEs will be coded using the Medical Dictionary for Regulatory Activities (MedDRA)
Changes in clinical laboratory safety tests	After 2, 4, 6, and 8 weeks of treatment and 4 weeks after EoT	serum biochemistry, safety haematology, and urinalysis
Changes in 12-Lead ECG	after 2, 4, 6, and 8 weeks of treatment and 4 weeks after EoT.	ventricular rate, PR interval, QRS duration, QT interval and QTcF
Changes in blood inflammatory markers	from baseline after 2, 4, 6, and 8 weeks of treatment and 4 weeks after EoT	high sensitivity C-reactive protein, interleukin 1 and interleukin 6, tumour necrosis factor alpha, soluble vascular cell adhesion molecule 1, endothelin-1, soluble platelet-selectin, and xanthine oxidase
Assessment of iron-related parameters and markers of erythropoiesis	from baseline after 2, 4, 6, and 8 weeks of treatment and 4 weeks after EoT	total serum iron, serum ferritin, serum transferrin, calculated TSAT, hepcidin, and erythropoietin
Change in patient reported outcomes	from baseline after 2, 4, 6 and 8 weeks of treatment.	using ASCQ-Me
Changes in abnormal RBCs (sickling)	baseline after 2, 4, 6 and 8 weeks of treatment and 4 weeks after EoT.	peripheral blood smear
Number of VOC episodes and visceral infarctions	over 8 weeks of treatment and 4 weeks after EoT.	VOC episodes
PK parameters	from pre-dose trough to 1 hour and 3 hours post- morning dose at selected study visits.	Cmax, clearance, distribution volume, AUC
Changes in haematological indices	from baseline after 2, 4, 6, and 8 weeks of treatment and 4 weeks after EoT.	Hb concentration, RBC count, Hct, MCV, MCH, MCHC, CHCM, RDW, WBC analyses including differential WBC counts, platelet and reticulocyte counts, percentage reticulocytes, percentage hypochromic microcytic RBCs (RBC volume versus Hb scatterplot analysis),
Physical examination findings	screening/Visit V1 (i.e., Day -14 to Day -1) and on Visits V2 (Day 1), V4 (Day 28), V6 (Day 56), and V7 (Day 84). Facultative physical examinations can be performed on indication, i.e., symptom-directed, on all other visits.	general appearance, head (eyes, ears, nose, and throat), cardiovascular, respiratory, abdominal, musculoskeletal, neurological, lymph nodes, and skin.
Vital signs	Vital signs should be performed before IMP administration (trough), after a resting period of at least 5 minutes in all visits	(blood pressure, pulse rate)
Mean change from baseline in haemolysis markers	after 8 weeks of treatment.	measured by direct and total bilirubin, lactate dehydrogenase (LDH), potassium, Hb and free haptoglobin



REPUBLIC OF LEBANON MINISTRY OF PUBLIC HEALTH Lebanon Clinical Trials Registry

Trial Results Summary results Study results globally Date of posting of results summaries Date of first journal publication of results **Results URL link Baseline characteristics** Participant flow Adverse events **Outcome measures** URL to protocol files